Form 4: MLYS CFO Sells Shares Under 10b5-1 Plan

Mineralys Therapeutics CFO Adam Levy sold 10,758 shares of common stock for a weighted-average price of $32.1364 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Adam Scott Levy, CFO and Secretary of Mineralys Therapeutics, Inc. (MLYS), reported a sale of common stock.
• The transaction involved the disposition of 10,758 shares of common stock on January 12, 2026.
• The shares were sold at a weighted-average price of $32.1364 per share, with individual transaction prices ranging from $31.90 to $32.37.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Levy on November 14, 2023.
• Following this transaction, Mr. Levy beneficially owns 8,638 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale is a pre-planned transaction under a 10b5-1 plan, which is a common practice for executive liquidity and diversification, and does not inherently signal a change in the company's fundamental outlook or management's confidence.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on new, non-public information, which enhances transparency and mitigates concerns about opportunistic insider trading.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct ownership stake of a key executive in the company.

Risks

• While a 10b5-1 plan mitigates the risk of trading on inside information, some investors may still perceive insider selling as a potential negative signal regarding management's long-term confidence, which could lead to minor short-term price volatility.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction; it solely reports an insider transaction.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Industry Context

This Form 4 filing is specific to an insider transaction at Mineralys Therapeutics and does not provide broader industry context or trends. Insider transactions are a routine part of executive compensation and personal financial management across all industries.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for executive stock sales is a standard corporate governance practice in the U.S. public markets, aligning with best practices for managing insider trading risks. Companies like Pfizer, Merck, and Johnson & Johnson frequently disclose similar pre-arranged sales by their executives.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the reduction in direct insider ownership, though mitigated by the 10b5-1 plan, as a minor signal, but generally, such pre-planned sales are not considered a strong indicator of future performance.
• Employees: No direct impact mentioned.

Next Steps

• The company or the reporting person may provide full information regarding the number of shares sold at each separate price within the reported range upon request from the Issuer, any securityholder, or the SEC staff.

Key Dates

Recommendation

The sale by the CFO was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information. This type of transaction is generally considered routine for executive liquidity and diversification, and does not inherently signal a change in the company's fundamental outlook. Therefore, a 'hold' recommendation is appropriate as this event alone does not provide a strong catalyst for a 'buy' or 'sell' decision.

Keywords

Mineralys Therapeutics, MLYS, Adam Levy, CFO, insider trading, 10b5-1 plan, stock sale, common stock, beneficial ownership